The Latest Breaking News from Pascal Soriot

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional" cancers that make the disease the leading cause of death worldwide, which is why Morgan Stanley forecast the radiopharma…

Editorial: The latest High Pay Centre report confirms the persistent and damaging culture of entitlement at the top of business

AstraZeneca’s Pascal Soriot and Rolls Royce’s Tufan Erginbilgic were among the highest-paid FTSE 100 CEOs, but what they make still trails behind the average pay of S&P 500 CEOs.

Bosses of UK’s biggest companies are now paid 120 times more than average full-time worker in some instances

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care…

The former pharma laggard is in a race with Shell to be the first FTSE 100 stock to be valued at £200bn

UK’s biggest drugmaker says it plans to launch 20 major new medicines before the end of the decade

The growth will be fuelled by 20 new drugs that are set to launch this decade

Stellantis CEO Carlos Tavares had a compensation package worth $39.4 million in 2023, lower than any of the world's top 50 sports stars.

Soriot came under fire this month for his £18.7 million pay packet

Despite rebellion, approval of £18.7m package opens door to likelihood of US-style executive pay elsewhere